Skip to main content

Table 2 Risk Factors for isoniazid treatment interruptions among latent tuberculosis cases followed for 12 months

From: Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis

Predictors Unadjusted
HR (95% CI)
Adjusted
HR (95% CI)
Type of Patient
 Pediatric 0.87 (0.82, 0.93) 0.83 (0.78, 0.89)
 Recent Contact 0.74 (0.69, 0.81) 0.74 (0.68, 0.81)
 Other Adults 1.00 1.00
Gender
 Male 1.00 1.00
 Female 0.91 (0.86, 0.95) 0.90 (0.85, 0.94)
Ethnicity
 Non-Hispanic 1.00 1.00
 Hispanic 1.46 (1.38, 1.53) 1.54 (1.43, 1.66)
Race
 White 1.28 (1.19, 1.37) 1.26 (1.18, 1.36)
 Black 1.14 (1.06, 1.22) 1.57 (1.44, 1.70)
 Asian 0.58 (0.51, 0.66) 0.77 (0.67, 0.89)
 Other 1.00 1.00
Birth Origin
 U.S.-born 1.00 1.00
 Non-U.S.-born, ≤ 5 Years 1.34 (1.27, 1.41) 1.25 (1.18, 1.32)
 Non-U.S.-born, >  5 Years 1.24 (1.12, 1.37) 1.16 (1.04, 1.29)
HIV Co-infected
 No 1.00 1.00
 Yes 0.41 (0.31, 0.53) 0.39 (0.30, 0.51)
Diabetic
 No 1.00 1.00
 Yes 0.73 (0.57, 0.94) 0.77 (0.60, 0.98)
Other Immunosuppressive Conditions
 No 1.00 1.00
 Yes 0.59 (0.42, 0.85) 0.65 (0.46, 0.93)
  1. Notes: HR hazard ratio; * p-values are based on the Cox proportional hazards models